Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Dec;63(Pt 12):1638-1643.
doi: 10.1099/jmm.0.075507-0. Epub 2014 Sep 10.

In vitro activities of amphotericin B deoxycholate and liposomal amphotericin B against 604 clinical yeast isolates

Maria Teresa Montagna  1 , Grazia Lovero  1 , Caterina Coretti  1 , Osvalda De Giglio  1 , Domenico Martinelli  2 , Andrea Bedini  3 , Mario Delia  4 , Antonio Rosato  5 , Mauro Codeluppi  3 , Giuseppina Caggiano  1
Affiliations

In vitro activities of amphotericin B deoxycholate and liposomal amphotericin B against 604 clinical yeast isolates

Maria Teresa Montagna et al. J Med Microbiol. 2014 Dec.

Abstract

We determined the in vitro antifungal activity of liposomal amphotericin B (L-AmB) against 604 clinical yeast isolates. Amphotericin B deoxycholate (D-AmB) was tested in parallel against all the isolates. Susceptibility testing was performed according to the Clinical and Laboratory Standards Institute (CLSI) M27-A3 method. Overall, L-AmB was highly active against the isolates (mean MIC, 0.42 µg ml(-1); MIC90, 1 µg ml(-1); 97.2 % of MICs were ≤1 µg ml(-1)) and comparable to D-AmB (mean MIC, 0.48 µg ml(-1); MIC90, 1 µg ml(-1); 97.3 % of MICs were ≤1 µg ml(-1)). The in vitro activity of D-AmB and L-AmB was correlated (R(2) = 0.61; exp(b), 2.3; 95 % CI, 2.19-2.44, P<0.001). Candida albicans (mean MICs of D-AmB and L-AmB, 0.39 µg ml(-1) and 0.31 µg ml(-1), respectively) and Candida parapsilosis (mean MICs of D-AmB and L-AmB, 0.38 µg ml(-1) and 0.35 µg ml(-1), respectively) were the species most susceptible to the agents tested, while Candida krusei (currently named Issatchenkia orientalis) (mean MICs of D-AmB and L-AmB, 1.27 µg ml(-1) and 1.13 µg ml(-1), respectively) was the least susceptible. The excellent in vitro activity of L-AmB may have important implications for empirical treatment approaches and support its role in treatment of a wide range of invasive infections due to yeasts.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
Distribution of deoxycholate and liposomal amphotericin B minimum inhibitory concentrations (MIC) for 604 clinical yeast isolates.
See this image and copyright information in PMC

References

    1. Adler-Moore J., Proffitt R. T. (2002). AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience. J Antimicrob Chemother 49 (Suppl. 1), 21–30. 10.1093/jac/49.suppl_1.21 - DOI - PubMed
    1. Anaissie E., Paetznick V., Proffitt R., Adler-Moore J., Bodey G. P. (1991). Comparison of the in vitro antifungal activity of free and liposome-encapsulated amphotericin B. Eur J Clin Microbiol Infect Dis 10, 665–668. 10.1007/BF01975823 - DOI - PubMed
    1. Carrillo-Muñoz A. J., Quindós G., Tur C., Ruesga M. T., Miranda Y., del Valle O., Cossum P. A., Wallace T. L. (1999). In-vitro antifungal activity of liposomal nystatin in comparison with nystatin, amphotericin B cholesteryl sulphate, liposomal amphotericin B, amphotericin B lipid complex, amphotericin B desoxycholate, fluconazole and itraconazole. J Antimicrob Chemother 44, 397–401. 10.1093/jac/44.3.397 - DOI - PubMed
    1. Cifani C., Costantino S., Massi M., Berrino L. (2012). Commercially available lipid formulations of amphotericin B: are they bioequivalent and therapeutically equivalent? Acta Biomed 83, 154–163. - PubMed
    1. CLSI (2008). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved standard, 3rd edn, M27-A3. Wayne, PA: Clinical and Laboratory Standards Institute.

Publication types